Update on Aurora Kinase Targeted Therapeutics in Oncology. - Wikidata - wikimedia - TriplyDB

Update on Aurora Kinase Targeted Therapeutics in Oncology.

Update on Aurora Kinase Targeted Therapeutics in Oncology.

http://www.wikidata.org/entity/Q34941504

about

Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition.Development of o -Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors Optimization of Imidazo[4,5- b ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia A Novel Mechanism by Which Small Molecule Inhibitors Induce the DFG Flip in Aurora A Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells.Skp-cullin-F box E3 ligase component FBXL2 ubiquitinates Aurora B to inhibit tumorigenesis Calmodulin protects Aurora B on the midbody to regulate the fidelity of cytokinesis.Aurora kinase-A deficiency during skin development impairs cell division and stratification Aurora kinase inhibition induces PUMA via NF-κB to kill colon cancer cells.Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT.Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.Differential involvement of RalA and RalB in colorectal cancer.The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia.The centrosome as potential target for cancer therapy and prevention.Emerging cell-cycle inhibitors for pancreatic cancer therapy.Aurora B: hooking up with cyclin-dependent kinases.Emerging drugs for acute lymphocytic leukemia.Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).Inhibition of human DNA topoisomerase IB by nonmutagenic ruthenium(II)-based compounds with antitumoral activity.Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies.Discovery of 7-aryl-substituted (1,5-naphthyridin-4-yl)ureas as aurora kinase inhibitors.p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases.Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.Regulation of AURKC expression by CpG island methylation in human cancer cells.A small-molecule inhibitor targeting the AURKC-IκBα interaction decreases transformed growth of MDA-MB-231 breast cancer cells.Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer.Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): Overexpression of Aurora kinases A and B is associated with a poor prognosis.MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

P2860

Q27306356-9A3A7A6E-8D1E-4191-AC4E-0945411AF04E Q27670770-AE028ABA-DE2B-4BD1-8178-690821A5F958 Q27674324-AFF53E67-9E0D-4871-8BEC-2FEC39F8C30E Q27676768-0D6D0268-6BB2-44A2-85E6-730CE324945F Q27680538-35B4A785-7CE3-4507-90AA-B410E9CA0E06 Q28388125-E4127C1A-1F43-4BCE-AA23-D1A5E34278E4 Q28395452-13FAFEF1-10EF-4CF5-993F-63F3FBB6F2A0 Q28590357-124E6B6E-B144-4FC8-86D4-8150C6E83519 Q33579079-C06C5439-7BA1-48CA-AAF6-60A496C23D33 Q33917530-97CC92C0-3B5E-438F-9D7D-EE6FE2141219 Q34029020-EC6FEFA0-DC97-4A0E-BEDD-6226DDDED93D Q34576589-0FE25A19-4BA6-46A6-92FA-CD9BA96A12AE Q35289072-62B7D942-99CF-409E-942D-9F9218FE0DED Q35691904-7874DB6E-5A7C-4DE4-BEEB-BA451566E2A7 Q35832355-1E108B49-2E5C-4FA2-9F89-93575EE9365A Q36129983-216C67CA-ED89-4CA8-894D-65D524F61420 Q37013275-1372ACB8-46CE-4F9B-93C1-4753DC36E8F3 Q38050752-4D1AF86F-A227-4BC9-AB31-594E7E8B2A08 Q38051759-42135551-24F3-49D5-A717-34C2F0E26FE4 Q38057759-E1C3B048-50F6-4EE6-BD34-213B30AF003C Q38091235-ADE6ABDC-F95A-4C67-9C55-C2EC2874394C Q38172586-7F9A3E34-88E1-40ED-B163-EE78AB691C76 Q38223271-B183D0F3-1FB4-4A07-83D5-05C9733D18A4 Q38804392-031BE3D8-964D-4B88-8591-357EC298D4B1 Q38813996-390EEBAB-508F-4AD2-B57E-891AA5B98BD5 Q38841925-D55209D0-431A-4880-8C0D-07BEECE1EBF7 Q38872009-E556AC9B-8761-46B6-B22E-631956CD531D Q39001858-1E486B93-2F97-4E12-9CA3-9A56DA0808AF Q39055807-2C2B3EDF-F351-40B3-A257-EC03158EB738 Q39108757-89797361-19BD-479A-995B-2CDEFA8AE160 Q39244395-5F525387-78C0-47A2-8261-7747F89A3245 Q39388577-73B5D784-33FF-4B01-83D4-5F11F4AF6079 Q39429784-45D9496F-81B0-4958-9C96-51D9ED974F07 Q40922875-F100CE1A-A497-4B86-B774-C308AB20634E Q42378370-740C4A4B-E21B-4318-81F6-4187259E83C2 Q47119995-C0AF5725-76BE-4A8F-AE88-B5F82E271E3C Q47147843-07DEFEEE-1C34-4739-ADCB-F43229E2753D Q50890020-B11F391C-2F02-4BA8-B43C-E44C9F1CAC9D Q54498929-73CE7686-DFA8-4472-873B-447F97C9E098

P2860

Update on Aurora Kinase Targeted Therapeutics in Oncology.

http://www.wikidata.org/entity/Q34941504

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Update on Aurora Kinase Targeted Therapeutics in Oncology.

@ast

Update on Aurora Kinase Targeted Therapeutics in Oncology.

@en

Update on Aurora Kinase Targeted Therapeutics in Oncology.

@nl

type

label

Update on Aurora Kinase Targeted Therapeutics in Oncology.

@ast

Update on Aurora Kinase Targeted Therapeutics in Oncology.

@en

Update on Aurora Kinase Targeted Therapeutics in Oncology.

@nl

prefLabel

Update on Aurora Kinase Targeted Therapeutics in Oncology.

@ast

Update on Aurora Kinase Targeted Therapeutics in Oncology.

@en

Update on Aurora Kinase Targeted Therapeutics in Oncology.

@nl

P1433

Q34941504-A2B95EC1-DFFC-4B07-B58F-4BD03643B912

P1476

Q34941504-A6FD4E63-8AB8-413F-BAE1-5829CB20B3D8

P2093

Q34941504-187BA68F-33A6-4FE4-8348-82C4D6EBA293

Q34941504-26FBE0F7-1FF0-48E7-9CC8-9125295ECD7F

Q34941504-86ABB56B-4CAD-49A6-82C4-A7E4856D41C4

P2860

Q34941504-0C7B1467-075F-4A0B-836E-5D5E7AF592F7

Q34941504-13FF7E1A-731B-4C81-9BD4-540690A4DF5C

Q34941504-1CB8C015-CF19-4D0C-AC95-DB118E082638

Q34941504-1D290F76-F4A9-4983-B3E8-2A25834151BD

Q34941504-1D6D9106-952F-40E8-A287-F017CB54F550

Q34941504-1EA3A931-2F1A-49E0-B482-AD8056B08507

Q34941504-242017B3-5015-444B-BBBC-90FE494EC2BB

Q34941504-2615F0FB-6EAD-43F9-B849-6925D3BABDC6

Q34941504-26C3CC21-24C1-4200-B8D7-FFFA8E9E9F24

Q34941504-29C35909-2D0E-4E93-8980-9B66DB124154

P304

Q34941504-E8B0E4FF-37E9-4768-BD5B-562F4837724A

P31

Q34941504-82E1C34B-2149-48A4-80B3-1251C28E4CAD

P356

Q34941504-F7F707BE-5872-46AB-A332-E83CA3294307

P407

Q34941504-8AEFEC00-A56D-46BD-A672-A2ED972B719C

P433

Q34941504-2270A18F-B62C-4266-99AC-066AA99D832B

P478

Q34941504-06C27CA5-5462-4501-B89E-0A77ED0B23B8

P577

Q34941504-A74DD574-DECC-422E-8E5B-876FD0E6403D

P5875

Q34941504-3E35F3DA-5F75-4F84-A6BA-481A04938918

P698

Q34941504-E32C40CB-47DF-4B32-B80E-ECAD5358049F

P932

Q34941504-AD4F9E67-A78C-4539-B9F6-54B4E2B90D1E

P356

17460441.2011.555395

P1433

Expert Opinion on Drug Discovery

P1476

Update on Aurora Kinase Targeted Therapeutics in Oncology.

@en

P2093

Daruka Mahadevan

http://www.w3.org/2001/XMLSchema#string

Joseph E Woolery

http://www.w3.org/2001/XMLSchema#string

Myke R Green

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of a potent and selective aurora kinase inhibitor

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

The cellular geography of aurora kinases

MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy.

Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

P304

291-307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17460441.2011.555395

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51111447

http://www.w3.org/2001/XMLSchema#string

P698

21556291

http://www.w3.org/2001/XMLSchema#string

P932

3088914

http://www.w3.org/2001/XMLSchema#string